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Abstract. Despite the progressive nature of Alzheimer’s disease and other dementias, it is observed that many individuals that
are diagnosed with mild cognitive impairment (MCI) in one clinical assessment, may return back to normal cognition (CN) in
a subsequent assessment. Less frequently, such ‘back-transitions’ are also observed in people that had already been diagnosed
with later stages of dementia. In this study, an analysis was performed on two longitudinal cohort datasets provided by 1)
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and 2) the National Alzheimer’s Coordinating Centre (NACC).
The focus is on the observed improvement of individuals’ clinical condition recorded in these datasets to explore potential
associations with different factors. It is shown that, in both datasets, transitions from MCI to CN are significantly associated
with younger age, better cognitive function, and the absence of ApoE 4 alleles. Better cognitive function and in some cases
the absence of ApoE 4 alleles are also significantly associated with transitions from types of dementia to less severe clinical
states. The effect of gender and education is not clear-cut in these datasets, although highly educated people who reach MCI
tend to be more likely to show an improvement in their clinical state. The potential effect of other factors such as changes in
symptoms of depression is also discussed. Although improved clinical outcomes can be associated with many factors, better
diagnostic tools are required to provide insight into whether such improvements are a result of misdiagnosis, and if they are
not, whether they are linked to improvements in the underlying neuropathological condition.
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INTRODUCTION
Despite the progressive nature of many neurode-
generative disorders and the absence of curative treat-
ments, in longitudinal cohort studies, where measure-
ments are made at a series of time points, it is observed
that the clinical condition of cognitively impaired
individuals may improve irrespective of their disease
severity. Such observations are frequent in many stud-
ies that have been designed to provide insights into the
progression of Alzheimer’s disease (AD) and other
types of dementia (for such studies see [1–11]).
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The limited knowledge on the pathogenesis, devel-
opment and progression of such diseases, and the
currently available diagnostic and assessment tools,
make it difficult to assess whether the observed
improvement of the clinical status is correct, and if it
is correct, whether it is connected to a real improve-
ment in the underlying neuropathological condition.
In any case, the accurate diagnosis of the clinical
state is challenging. Factors that can affect the clin-
ical diagnosis vary. The underlying causes of signs
and symptoms associated with AD and other demen-
tias can be masked by the presence of confounding
comorbid conditions [9, 14] and emotional problems
(e.g., grief, stress, depression, psychosis, fatigue) or
other brain conditions. Poor methodologies and tools
used for clinical assessment, the lack of resources, as
well as patient factors such as communication prob-
lems [15] and practice effects [16–18] have also been
reported as significant factors that can influence accu-
rate diagnosis. Other factors suggested by various
studies include adjustments of medication and thera-
pies such as memantine and cholinesterase inhibitors
developed to manage AD symptomology, resistance
to cognitive decline due to cognitive reserve, lifestyle
factors (e.g., alcoholism and substance abuse), and
normal aging changes [1, 6, 9, 19–21].
In this study we investigate whether there are sig-
nificant factors, including demographic and genetic,
associated with the observed cognitive improve-
ments. Generalized linear mixed models (GLMM)
are developed. We focus our analysis on the tran-
sitions between three commonly recognized clinical
states, namely, the cognitively normal (CN), the mild
cognitive impairment (MCI), and the dementia (D)
state. In particular, we analyze the data from individ-
uals that were classified in the MCI or dementia state
in one of the assessments, and had the possibility of
transitioning backwards to an earlier state in a subse-
quent assessment. Two different longitudinal cohort
datasets are utilized; the Alzheimer’s Disease Neu-




The first dataset employed in the analyses was
obtained from the Alzheimer’s Disease Neuroimag-
ing Initiative (ADNI, http://adni.loni.usc.edu, last
downloaded 2016/10/31). ADNI was launched in
2003 as a public-private partnership, led by Principal
Investigator Michael W. Weiner, MD. The primary
goal of ADNI has been to test whether serial magnetic
resonance imaging (MRI), positron emission tomog-
raphy (PET), other biological markers, and clinical
and neuropsychological assessment can be combined
to measure the progression of MCI and early AD.
For up-to-date information, see http://www.adni-
info.org.
ADNI is a multisite (50 ADNI clinical trial sites
are located across the US and Canada), longitu-
dinal study of normal cognitive aging, MCI, and
early AD individuals. The ADNI study has three
phases: ADNI-1, ADNI-GO, and ADNI-2. Important
to note that ADNI is not a population-based study. Its
population represents a primarily amnestic clinical
population that can be used in treatment trials. Partic-
ipants were recruited following specific recruitment
methods.
The original dataset obtained from ADNI consists
of 1,737 individuals (from the ADNI-1, ADNI-GO,
and ADNI-2 protocols). 106 participants (of ADNI-
2) were categorized as ‘Significant Memory Concern’
(SMC). The key inclusion criteria that distinguish
SMC are a self-report significant memory concern
from the participant, although participants in this
class scored within normal range for cognition (or
Clinical Dementia Rating = 0). However, this is not
equated as progressive memory impairment or as con-
sistent forgetfulness. SMC individuals were excluded
from our analysis, so that in both datasets analyzed in
this study, only transitions between CN, MCI, and D
are considered. In addition, there were 7 individuals
that had only a screening visit/diagnosis (preceding
the baseline visit/diagnosis) and were also excluded
from the study. The study duration up to the time the
current analysis was performed is about 11 years.
The second dataset used was provided by the
National Alzheimer’s Coordinating Center (NACC,
http://alz.washington.edu). NACC was established
by the National Institute on Aging/NIH (U01
AG016976) in 1999. It develops and maintains a
cumulative database including clinical evaluations,
neuropathology data when available, and MRI imag-
ing [23]. The data are contributed by the 39 past and
present Alzheimer’s Disease Centers (ADCs) using
a prospective, standardized, and longitudinal clinical
evaluation of the subjects in the National Institute
on Aging’s ADC Program. Each center enrolls its
subjects according to its own protocol. Subjects
are enrolled through clinician referral, self-referral,
referral by family members, or active recruitment
through community organizations. They may also be
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volunteers who wish to contribute to the studies.
Diagnosis is made by either a consensus team or a sin-
gle physician, but the actual process varies according
to each ADC’s protocol.
The analysis in the current study was based on
data from visits conducted between September 2005
(start date of the Uniform Data Set) and June 2016
(data freeze). This specific dataset consists of 9,927
individuals. The clinic-based population of NACC
includes subjects with AD and related disorders, as
well as CN and MCI subjects. There is also a state,
described as ‘Impaired, not MCI’ (INM), for those
individuals whose presentation, tests, symptoms and
clinical evaluation do not fit into the normal cogni-
tion, MCI, or dementia criteria. For comparison with
ADNI, in NACC, the visits at which someone is clas-
sified as INM are ignored (1,667 INM classifications
out of 47,434). The longest follow-up in NACC, up to
the time the current analysis was performed, is about
10 years.
It should be noted that in both ADNI and NACC
datasets that we consider, the majority of individuals
that developed dementia was due to AD. In partic-
ular, in ADNI only 18 (2.6%) and in NACC only
337 (3.4%) individuals developed dementia that was
not due to AD (note that ADNI focuses on amnestic
MCI subtype and any significant neurologic disease
other than AD is an exclusion criterion). The proce-
dure of AD clinical diagnosis in NACC depends on
the actual diagnostic protocol of the ADC, but as in
ADNI, each center generally adheres to standardized
clinical criteria as outlined by the NINCDS-ADRDA
guidelines [24]. It should be acknowledged, however,
that autopsy-verified diagnoses have confirmed that
neuropathologic comorbidities are common among
cases with neuropathologic AD [11, 12, 29, 30]. Such
comorbidities can increase the rate of progression to
more severe cognitive impairment states [9, 10]. It
has also been verified that some clinically diagnosed
MCI and AD individuals may not even present AD
neuropathologic changes [9].
Key criteria for MCI diagnosis in ADNI include
Mini–Mental State Examination (MMSE) scores
between 24–30 (inclusive), a memory complaint,
objective memory loss measured by education
adjusted scores on Wechsler Memory Scale Logical
Memory II, a Clinical Dementia Rating of 0.5,
absence of significant levels of impairment in other
cognitive domains, essentially preserved activities
of daily living, and absence of dementia. Standard
criteria were used to diagnose MCI in NACC (the
participant is neither normal nor demented, there
is evidence of cognitive deterioration and there are
normal functional activities) [25, 26]. For a detailed
list of all diagnostic, inclusion and exclusion criteria
readers are referred to the ADNI Procedures Manual
(http://adni.loni.usc.edu/methods/documents) and
NACC protocols (http://alz.washington.edu). It is
worth noting that, in both datasets, different MCI
subtypes have been defined. Two major subtypes
of MCI, amnestic and non-amnestic MCI, are
recognized. Each subtype can be further subdivided
into single and multiple domain types. In NACC,
all subtypes are included whereas all enrolled
MCI subjects in ADNI are amnestic MCI, as these
subtypes progress to AD at a high rate. In addition,
in ADNI 2, MCI is divided further into ‘Early MCI’
(EMCI) and ‘Late MCI’ (LMCI). In both datasets,
we have combined the MCI subtypes (but see for
example [6]).
Factors considered
We are interested in the effect of the following fac-
tors on the likelihood of MCI or D individuals moving
to a less severe state in subsequent assessments:
Chronological age: exact age of individuals at the
point of assessment.
Gender: male or female.
Education: we considered education as a factor that
could increase resistance to cognitive decline. We
focused on two different groups: one consisting of
individuals that have completed 12 years of educa-
tion and one of individuals that have more than 12
years of education.
Genetic background: absence or presence of one or
two alleles of the apolipoprotein 4 genotype (APOE
4, homozygous or heterozygous), a well-known risk
factor of AD.
Time between visits: time between clinical assess-
ments (in years).
Cognitive performance: We are interested in a
number of commonly used measures of cognition.
We focused on the scores in an Alzheimer’s Disease
Assessment Scale-Cognitive Subscale test (ADAS-
Cog 11) and the scores in the MMSE test. The original
ADAS-Cog 11 [27] includes 11 items assessing cog-
nitive function (including memory, language, praxis,
and orientation). Higher scores reflect greater cogni-
tive impairment and the maximum score of the test
is 70 points. Additional analysis including ADAS-
Cog 13-item scale [28], which consists of all items
of the original ADAS-Cog 11 test plus two addi-
tional tasks, yielded similar results and has not been
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considered further in this study. MMSE [29] is a 30-
point questionnaire which also measures cognitive
impairment, with a lower score indicating greater
severity. ADAS-Cog 11 and ADAS-Cog 13 scores
are available in ADNI. MMSE scores are available
in both ADNI and NACC. It should be noted that
MMSE score is one of the criteria used for the clin-
ical diagnosis of participants in ADNI, and also one
of the most widely used test of dementia severity in
NACC [30].
Depression scores (Geriatric Depression Scale,
GDS): These are scores from a screening test
designed to identify depression symptoms in the
elderly. A 15-item GDS bigger or equal to 6 was an
exclusion criterion in ADNI. Individuals with history
of major depression or bipolar disorder within the
past year were also excluded from the study. In
NACC, GDS is not recorded for individuals with
severe dementia, but it is not used as an exclusion
criterion for study entry. It should be noted, however,
that GDS is not a required form in NACC, so it may
not be recorded for any participant at any visit. Due
to the inclusion/exclusion criteria and the reduced
number of assessments of the GDS score in the
datasets considered, the results and conclusions
about the potential effect of depression should be
interpreted with extra caution.
Statistical models/analysis
Individuals were classified in three clinical states:
CN, MCI and D. We focused on MCI→CN, D→MCI
and D→CN as the possible back-transitions during
disease development. In ADNI, there were no direct
transitions from D back to CN. In NACC, 43 such
transitions were observed. The possible transitions
between the different states are as shown in the
schematic diagram of Fig. 1.
For the analysis of the back-transitions and
associated factors, we first considered each factor
independently. We calculated descriptive statistics
and created box-and-whisker plots to illustrate the
available data and differences in the median and
variability of factors of interest in the group of par-
ticipants that have moved backwards at least once
and those that have never moved backwards. In this
case, in order to avoid time effects and to make fair
comparisons between individuals and datasets, only
the clinical state at the beginning and the end of each
year was considered. Thus, in ADNI, only for this
analysis, any transitions at the 6-month and 18-month
visits (see ADNI Procedures Manual; note that not all
participants have been assessed at these time points)
have not been taken into account in the transitions
of year 1 and year 2, respectively. In the statistical
models that we developed and describe below, all
transitions of interest between any two recorded visits
were included, regardless of the time between them.
For this reason, we included the ‘time between visits’
variable, so that we account for the fact that the time
between visits is varying.
In order to study the overall impact of the factors
presented in the previous section on the likelihood
of transitioning to a less severe clinical state from
a more severe one, we developed a generalized lin-
ear mixed model (GLMM). GLMMs are an extension
Fig. 1. Schematic diagram showing the possible health and disease states in which one individual can be classified in the present study
and potential transitions between these states. Observable back-transitions of individuals from Mild Cognitive Impairment to Cognitively
Normal state, and from Dementia to Mild Cognitive Impairment and Cognitively Normal states are questionable; they might be real, or just
due to different factors that can affect the accuracy of the diagnosis.
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of the generalized linear model (GLM) that include
both fixed and random effects. They are useful for
studying longitudinal data by accounting for the non-
independence of observations between subjects or
groups (by the addition of one or more random inter-
cept or slope terms).
GLMMs with a logit link function were used with
the probability of transitioning to a less severe state
as the response variable.
A series of models were developed; model 1 (the
base model), model 2a, model 2b, and model 3.
Model 1, the base model:This model was devel-
oped to assess the individual impacts of the main
demographic and genetic factors holding all else
constant. In particular, the base model, as well as
all subsequent models in which the base model is
nested, included the same fixed effects for all com-
binations of ADNI/NACC and MCI/D transitions:
age at visit (centered at 50 years of age), gen-
der, education, ApoE 4 status, and time since last
visit (centered at one year). Unique subject iden-
tifier/Roster ID (RID) was included as a random
factor (random intercept) in all models to incor-
porate the correlation between observations from a
single individual, thus accounting for the repeated
measure data structure of longitudinal studies. The
RID variable can also be interpreted as account-
ing for, to some extent, any differences between
individuals that have not already been represented
by other variables in the analysis. These differ-
ences can be due to a number of other factors, for
example, medical conditions or psychosocial fac-
tors. The Intraclass Correlation Coefficient (ICC)
was used to assess the proportion of the total vari-
ation that is explained by the way in which repeated
observations are clustered within individuals. In other
words, the ICC helps to inform the extent to which
the likelihood of back-transitioning is due to the dif-
ferences between individuals after having accounted
for the other explanatory variables.
Models 2a and 2b: The impact of the cognitive
functions as assessed by the scores in MMSE and
ADAS-Cog 11 tests were considered in model 2a
and model 2b, respectively, by adding a new vari-
able coded for each of these tests to the base model
in an iterative manner. Since the cognitive scores are
used as diagnostic criteria and it is expected that indi-
viduals classified to less severe states do better in
cognitive tests, in the models we incorporated the
scores only at the MCI and D diagnosis of the pre-
vious assessment (i.e., before the MCI→CN/MCI/D
and D→CN/MCI/D transitions).
Model 3: The potential impact of depression on
the occurrence of back-transitions was considered by
incorporating in the base model the GDS of individu-
als relative to their previous visit, with positive values
indicating potential increased depression since their
previous visit.
To estimate the parameters of the models, sub-
sets of each of the main datasets were used based
on whether we were considering transitions to less
severe states starting from MCI or D. A new vari-
able, ‘previous diagnosis’, was derived and used
to subset the data based on previous diagnoses of
either MCI or D. Whether an individual did or did
not transition to a less severe state at the visit in
question was then determined by comparing the diag-
nosis at the visit with the diagnosis at their previous
visit.
GLMMs were implemented using the R2MLwiN
package in R [31]. Statistical significance was cal-
culated using a 95% confidence level. More details
about the statistical model and the fitting procedure
are provided in the Supplementary Material A.
RESULTS
The analysis of the two datasets, ADNI and NACC,
shows that a significant number of participants moved
to a previous clinical state during the disease develop-
ment cascade. The number of individuals that moved
backwards (either from MCI to CN or from D to CN
or MCI) at least once within a year is presented in
Table 1. In ADNI, out of the 855 individuals that
reached MCI, 73 (i.e., 8.54%) individuals moved
back to CN. A lower proportion has moved back-
wards to MCI after reaching dementia. In particular,
out of the 497 individuals that reached the dementia
state, 17 (i.e., 3.42%) moved at least once back to
MCI. In NACC, a very high proportion of individ-
uals (607 out of the 2,764 individuals, i.e., 21.96%)
that reached MCI transitioned back to the CN state.
This higher proportion of backward transitions from
the MCI state that is observed in NACC might be due
to the different subtypes of MCI that are included in
this dataset. 150 of 4,002 (3.75%) individuals previ-
ously diagnosed with dementia moved back to MCI
within a year, a proportion similar to that observed
in ADNI. 30 of these demented individuals (0.75%)
have directly transitioned backwards to CN.
As shown in Supplementary Figure B1, some
of the participants have moved between MCI and
CN at least five times (3 MCI→CN transitions).
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Table 1
Proportion of individuals that transitioned at least once within one year from MCI to CN and from D to CN or to MCI, in each sub-group
in ADNI and NACC. It should be noted that here, for comparisons, any transitions at the 6-month and 18-month visits in ADNI have not
been taken into account in the transitions of year 1 and year 2, respectively. PX−{} denotes the number of individuals in each sub-group that
transitioned at least once within one year from state X to any of the states in {}
PMCI→{CN}/ PD→{CN}/ PD→{MCI}/
PMCI→{CN, MCI, D} PD→{CN, MCI, D} PD→{CN, MCI, D}
ADNI NACC ADNI NACC ADNI NACC
Total in the datasets 73/855 607/2,764 0/497 30/4,002 17/497 150/4,002
considered (8.54%) (21.96%) (0%) (0.75%) (3.42%) (3.75%)
Chronological ≤70 39/277 222/746 0/121 10/1,138 6/121 39/1,138
age at baseline (14.08%) (29.76%) (0%) (0.88%) (4.96%) (3.43%)
70<Age≤80 25/408 231/1,187 0/264 18/1,655 9/264 67/1,655
(6.13%) (19.46%) (0%) (1.09%) (3.41%) (4.05%)
>80 9/170 154/831 0/112 2/1,209 2/112 44/1,209
(5.29%) (18.53%) (0%) (0.16%) (1.79%) (3.64%)
Gender Women 34/351 329/1,455 0/205 16/2,144 5/205 70/2,144
(9.69%) (22.61%) (0%) (0.75%) (2.44%) (3.26%)
Men 39/504 278/1,309 0/292 14/1,858 12/292 80/1,858
(7.74%) (21.24%) (0%) (0.75%) (4.11%) (4.31%)
Years of education∗ ≤12 4/136 145/707 0/102 8/1,387 3/102 49/1,387
(2.94%) (20.51%) (0%) (0.58%) (2.94%) (3.53%)
>12 69/719 461/2,052 0/395 22/2,592 14/395 101/2,592
(9.60%) (22.47%) (0%) (0.85%) (3.54%) (3.90%)
Genetic non-carriers 45/427 363/1,368 0/165 18/1,419 7/165 67/1,419
Background (10.54%) (26.53%) (0%) (1.27%) (4.24%) (4.72%)
(ApoE 4)∗ Carriers of 26/337 146/811 0/235 10/1,455 9/235 43/1,455
1 4 allele (7.71%) (18.00%) (0%) (0.69%) (3.83%) (2.95%)
Carriers of 2/91 17/169 0/97 1/430 1/97 7/430
2 4 alleles (2.20%) (10.06%) (0%) (0.23%) (1.03%) (1.63%)
∗Note that in NACC, the educational attainment was not recorded for all individuals. Similarly for the presence or absence of any ApoE ε4
in both ADNI and NACC.
On the other hand, previously diagnosed CN indi-
viduals have been classified in the MCI state in a
significant number of consecutive assessments (up
to 4 assessments in NACC) before their classifica-
tion back to the CN state. Previously diagnosed MCI
individuals have also been diagnosed with demen-
tia in a number of consecutive assessments (up to 4
in ADNI and 5 in NACC) before their classification
again into the MCI state (see Supplementary Table
B1). These results exclude the large number of tran-
sitions of individuals who entered the studies as MCI
or D and transitioned backwards to CN or MCI, as
the time since the transition to MCI or D diagnosed at
the beginning of the study is unknown. Supplemen-
tary Table B2 shows the number of these transitions.
It is observed that in some cases individuals that have
been classified in either MCI or D at baseline have
remained in these states even in ten and eight consecu-
tive assessments, respectively (in duration of up to ten
and eight years, respectively) before their movement
back to CN or MCI states.
Figure 2 shows box-and-whisker plots of age, years
of education, ADAS-Cog 11, and MMSE scores at
the visit where participants that had reached MCI
or D in the assessment of the previous year moved
backwards, and at the visit where participants that
had reached MCI or D in the previous year remained
either at the same state or moved forward. Figure 3
shows box-and-whisker plots to illustrate differences
in ADAS-Cog 11 and MMSE scores at the point of
previous diagnosis between back-transitioners and
those who have never transitioned backwards.
Analysis of the output of the statistical models
The inclusion and exclusion criteria that have been
used for the development of the base model yielded
data from 1,208 participants in ADNI and 4,941
in NACC. These are participants that have reached
either MCI or D and had the chance to transition to
a previous clinical state in a subsequent visit. The
baseline characteristics of these participants and other
features are presented in Table 2. It should be noted
that this is also a good representation of the charac-
teristics of the sample used in the other models. The
significance of the effect of the factors considered
in the base model on the occurrence of MCI→CN
transitions is presented in Table 3. Table 4 shows the
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Fig. 2. Box-and-whisker plots indicating differences in the median and variability of age, years of education, ADAS-Cog 11 and MMSE
scores, between 1) those that transitioned from MCI to CN (MCI→CN) and those that transitioned from MCI to D (MCI→D) or remained
at MCI (MCI→MCI), when assessed one year after the MCI diagnosis; and 2) those that transitioned from D to CN or MCI (D→CN/MCI)
and those that remained at D (D→D), when assessed one year after the D diagnosis. The values presented are at the point of last diagnosis,
i.e., at the point of the CN, last MCI, and D diagnoses for the MCI→CN, MCI→MCI, and MCI→D transitions, respectively, and at the
point of the CN, MCI, and last D diagnoses for the D→CN, D→MCI, and D→D transitions, respectively. For the years of education, we
compared those individuals that transitioned backwards at least once during the course of the study against those that remained at the same
state or moved forward (and never backwards), so that to avoid taking into account multiple times the education of a single individual.
potential influence of these factors on D→CN/MCI
transitions. The additional influence of cognitive per-
formance and GDS as considered in Model 2 and
Model 3 are presented in the Supplementary Tables
C1-C6.
Chronological age: Age is shown to be a significant
factor associated with back-transitions from MCI to
CN in both ADNI and NACC datasets (see Table 3).
In particular, younger individuals are more likely to
move backwards after an MCI diagnosis. Although
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Fig. 3. Box-and-whisker plots indicating differences in the median and variability of ADAS-Cog 11 and MMSE scores, between 1) those
that transitioned from MCI to CN (MCI→CN) and those that transitioned from MCI to D (MCI→D) or remained at MCI (MCI→MCI),
when assessed one year after the MCI diagnosis; and 2) those that transitioned from D to CN or MCI (D→CN/MCI) and those that remained
at D (D→D), when assessed one year after the D diagnosis. The values presented are at the point of previous diagnosis, i.e., at the point of
the first MCI diagnosis for the MCI→CN, MCI→MCI, and MCI→D transitions and at the point of the first D diagnosis for the D→CN,
D→MCI, and D→D transitions.
age is not significantly associated with transitions
from D to MCI, the results also show that younger
individuals tend to be more likely to move backwards
when they reach the dementia state (Table 4, see also
Fig. 2). This may suggest that younger individuals can
better tolerate potential brain changes than older peo-
ple and consequentially maintain a better test result.
Gender: Although statistical significance was not
achieved for gender, in most of the cases, the output of
the model suggests that there is a trend toward higher
likelihood of transitioning back to CN from the MCI
state for females (see Table 3), whereas males are
more likely to move from dementia back to CN and
MCI states in a subsequent assessment (see Table 4,
see also the difference in the proportions of women
and men that moved backwards from MCI and D in
Table 1).
Education: Utilizing the ADNI dataset, the base
model suggests that education is also a significant
factor associated with MCI→CN transitions, with
highly educated people (>12 years of education)
being more likely to move back to the CN state after
their classification in the MCI state in the previous
assessment (see Table 3). A significant association
between education and the occurrence of MCI→CN
transitions is not verified when NACC data is used.
However, even in NACC a high number of years
of education seems to increase the likelihood of
CN diagnosis in already diagnosed MCI individu-
als. The effect of education, as suggested by the
output of the models, might be a feature of cog-
nitive reserve of educated people and their ability
to temporarily resist apparent cognitive decline, at
least at earlier states in disease development. At the
dementia state the effect of education is question-
able in both studies, perhaps due to the small sample
sizes; no significant association was found, and Odds
Ratio >1 in ADNI, whereas Odds Ratio <1 in NACC
(Table 4).
Genetic background: In NACC, it is shown that
the presence of ApoE 4 alleles is significantly asso-
ciated with the occurrence of back-transitions, with
ApoE 4 carriers being less likely to move backwards
either from MCI or D. This was not confirmed in
ADNI where only the presence of two alleles of ApoE
4 was shown to be a significant factor associated
with MCI→CN transitions. However, carriers of one
ApoE 4 allele in ADNI also tend to be less likely to
move backwards in disease development from any of
the clinical states.
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Table 2
Baseline number and characteristics of individuals in ADNI and NACC datasets that have been used in the base model. The datasets used
consist of those individuals that have reached either MCI or D and had the chance to transition backwards in a subsequent assessment. Data
on all characteristics that are incorporated into the base model is available. It should be noted that the table also provides a good description
of the sample used for the development of the other statistical models
Dataset
ADNI NACC
Total number of individuals considered 1,208 4,941
Cognitive state at baseline CN MCI D CN MCI D
Total number of individuals at each state 67 827 314 724 1,753 2,464
(5.55%) (68.46%) (25.99%) (14.65%) (35.48%) (49.87%)
Chronological age 70 7 279 76 147 540 788
(0.58%) (23.10%) (6.29%) (2.97%) (10.93%) (15.95%)
70<Age≤80 47 384 156 286 762 981
(3.89%) (31.79%) (12.91%) (5.79%) (15.42%) (19.85%)
>80 13 164 82 291 451 695
(1.08%) (13.58%) (6.79%) (5.89%) (9.13%) (14.07%)
Gender Women 28 334 140 435 879 1,323
(2.32%) (27.65%) (11.59%) (8.80%) (17.79%) (26.78%)
Men 39 493 174 289 874 1,141
(3.23%) (40.81%) (14.40%) (5.85%) (17.69%) (23.09%)
Years of education ≤12 8 141 76 172 434 892
(0.66%) (11.67%) (6.29%) (3.48%) (8.78%) (18.05%)
>12 59 686 238 552 1,319 1,572
(4.88%) (56.79%) (19.70%) (11.17%) (26.69%) (31.81%)
Genetic Background (ApoE 4) non-carriers 43 403 100 482 977 1,011
(3.56%) (33.36%) (8.28%) (9.75%) (19.77%) (20.46%)
Carriers of 21 332 151 218 624 1,107
1 4 allele (1.74%) (27.48%) (12.50%) (4.41%) (12.63%) (22.40%)
Carriers of 3 92 63 24 152 346
2 4 alleles (0.25%) (7.62%) (5.21%) (0.49%) (3.08%) (7.00%)
Other characteristics (standard deviation of the mean in brackets)
Average age 75.49 73.10 74.80 77.68 74.41 74.21
(5.26) (7.52) (7.69) (9.11) (9.02) (9.83)
Years of education 15.18 15.96 15.92 15.21 15.29 14.35
(2.96) (2.76) (2.85) (3.25) (3.33) (3.71)
ADAS-Cog 11 score 6.82 10.35 19.39 – – –
(2.97) (4.57) (6.68)
MMSE score 29.06 27.58 23.30 28.56 27.12 21.14
(1.09) (1.81) (2.05) (1.54) (2.38) (5.68)
Time between visits (years)∗ 0.95 0.76 0.63 1.19 1.16 1.12
(0.39) (0.34) (0.24) (0.53) (0.51) (0.43)
Total follow-up (years) 7.04 3.77 1.56 5.44 4.18 3.81
(3.00) (2.13) (0.70) (2.00) (1.93) (1.72)
∗The 6-month and 18-month visits in ADNI have been taken into account.
Time between visits: In both ADNI and NACC, the
duration between two assessments is strongly asso-
ciated with the transition of MCI individuals back to
the CN state. Although statistical significance was
not shown for back-transitions from the dementia
state, in all the cases, the longer the duration between
two assessments, the higher the chance of individu-
als moving backwards from any of the disease states.
This might be related to the frequency of patient-
clinician contact, with the chance of a misdiagnosis
being increased when the patient is not assessed fre-
quently and adequately.
Unique subject identifier/Roster ID (RID): In
most models, a high proportion of the total variance
was explained by individual patient differences.
These could be unaccounted for measures such
as medications, but a high intra-class correlation
coefficient (ICC) also indicates that the probability of
transitioning back to a less severe clinical state varies
more between people, than within observations for
an individual.
Cognitive performance: The models incorporating
cognitive function that was assessed by MMSE and
ADAS-Cog 11 tests before back-transitions (Mod-
els 2a and 2b) suggest that the score in these tests
is significantly associated with both MCI→CN and
D→CN/MCI transitions, with individuals perform-
ing better in the tests being more likely to move
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Table 3
Potential factors associated with the MCI→CN transitions in the base model. n represents the number of assessments used to develop the
GLMMs, i.e., the number of MCI cases that had the chance to transition to a previous clinical state in a subsequent assessment. CI: credible
interval, SD: standard deviation, ICC: intraclass correlation coefficient, p: p-value, ∗: p ≤ 0.05, ∗∗: p ≤ 0.01, ∗∗∗: p ≤ 0.001
Base model, MCI→CN ADNI (n = 3,458) NACC (n = 5,642)
Fixed effects Odds Ratio (95% CI) p Odds Ratio (95% CI) p
Age at visit 0.93 (0.89, 0.98) ∗∗ 0.95 (0.94, 0.97) ∗∗∗
Gender (male+) 1.12 (0.55, 2.27) 1.28 (0.98, 1.67)
Education (≤12 years+) 5.29 (1.3, 21.53) ∗ 1.21 (0.87, 1.66)
ApoE 4, 1 allele (absence of ApoE 4+) 0.70 (0.33, 1.48) 0.43 (0.32, 0.59) ∗∗∗
ApoE 4, 2 alleles (absence of ApoE 4+) 0.17 (0.03, 0.93) ∗ 0.10 (0.05, 0.22) ∗∗∗
Time between visits 2.72 (1.34, 5.52) ∗∗ 1.30 (1.08, 1.57) ∗∗
Intercept 0.01 (0.00, 0.07) ∗∗∗ 0.27 (0.16, 0.46) ∗∗∗
Random effects Variance SD ICC Variance SD ICC
Roster ID (Intercept) 4.98 2.23 0.60 4.00 2.00 0.55
+Reference category.
Table 4
Potential factors associated with transitions from D to less severe states (CN or MCI) in the base model. n represents the number of
assessments used to develop the GLMMs, i.e., the number of dementia cases that had the chance to transition to a previous clinical state
in a subsequent assessment. CI: credible interval, SD: standard deviation, ICC: intraclass correlation coefficient, p: p-value, ∗: p ≤ 0.05,
∗∗: p ≤ 0.01, ∗∗∗: p ≤ 0.001
Base model, D→CN/MCI ADNI (n = 1,429) NACC (n = 10,167)
Fixed effects Odds Ratio (95% CI) p Odds Ratio (95% CI) p
Age at visit 0.95 (0.90, 1.01) 0.97 (0.94, 1.01)
Gender (male+) 0.48 (0.19, 1.25) 0.52 (0.25, 1.09)
Education (≤12 years+) 1.96 (0.51, 7.53) 0.78 (0.36, 1.69)
ApoE 4, 1 allele (absence of ApoE 4+) 0.83 (0.35, 1.96) 0.34 (0.15, 0.76) ∗∗
ApoE 4, 2 alleles (absence of ApoE 4+) 0.07 (0.01, 1.00) 0.07 (0.01, 0.32) ∗∗∗
Time between visits 3.00 (0.99, 9.10) 1.33 (0.81, 2.17)
Intercept 0.06 (0.01, 0.50) ∗∗ 6.1E-04 (7.0E-04, 5.5E-03) ∗∗∗
Random effects Variance SD ICC Variance SD ICC
Roster ID (Intercept) 0.078 0.28 0.02 21.08 4.59 0.87
+Reference category.
backwards in the subsequent assessment (see Sup-
plementary Tables C1-C4. See also Figs. 2 and 3).
Depression scores (GDS): When GDS is incorpo-
rated into the statistical model (Model 3), it is shown
that this is not a significant factor associated with the
occurrence of back-transitions (see Supplementary
Tables C5-C6). This may contradict conclusions of
previous studies suggesting that the presence of
depression might be an important determinant in the
misclassification of cognitively normal individuals in
more severe states due to poor performance in cog-
nitive tests [32]. However, as mentioned earlier, due
to the inclusion and exclusion criteria used in both
ADNI and NACC, and the reduced number of visits
where GDS was recorded, these findings and conclu-
sions should be subject to caution in interpretation.
DISCUSSION
There is no significant body of scientific evidence
as yet that suggests the condition of cognitively
impaired individuals developing a neurodegenera-
tive disease can improve over time, with or without
therapy. However, in the available observational lon-
gitudinal studies, it is clear that a significant number
of cognitively impaired and demented individuals
move to less severe clinical states or even recover
to a normal cognitive state.
We studied two large longitudinal cohort datasets,
ADNI and NACC, to explore factors that could be
associated with transitions of individuals to earlier
clinical states. In some cases, the analysis of the
datasets yielded different results. This can be partly
attributed to variation in recruitment and inclusion
criteria for the two cohort databases, differences in
the sample size and the demographic characteristics
of the sample in each diagnostic group, and other
differences in the protocols. The nature and level of
impairment and disease severity at the different clin-
ical states as defined in the two datasets could also
be an important factor. For example, in ADNI all
enrolled MCI subjects were amnestic MCI; amnes-
tic MCI may represent a more stable group and
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individuals in this group are more likely to convert
to clinically probable AD within a few years [33].
Hence, the occurrence of back-transitions from MCI
may be less frequent in ADNI than in NACC where
different types of MCI are included. In addition, both
datasets include data obtained from multiple longi-
tudinal aging studies. In NACC, the procedure of
clinical diagnosis, as well as the recruitment and
follow-up procedures, may vary according to the
protocol of each ADC. For example, some ADCs
diagnose participants blinded to the previous diag-
noses, and these centers have higher back-transition
rates (see also [10, 11]). ADNI is also a multisite,
multi-study program, and it is also observed that
back-transitions are more frequent in some sites than
in others. Extended models should incorporate dif-
ferent types of MCI. Whenever possible, they should
also control for research center and potentially for
clinician, so they account for variability due to the dif-
ferent ADCs and assessments by multiple clinicians
(see for example [9]).
Despite differences between the two datasets, anal-
yses suggest some underlying common patterns. It
was shown that in both datasets, younger individu-
als are more likely to recover to normal cognition
from an MCI state. Although not always a statistically
significant factor, education was also shown to play
an important role in the presence of back-transitions
with highly educated people being more likely to
move from MCI to CN state. This might support the
hypothesis that despite the presence of pathological
changes, young and highly educated individuals are
more resilient, leading to the absence of observable
clinical effects and delays in the accurate diagnosis
of mental state. The effect of gender is less clear-cut;
although the analysis showed that it is not a signifi-
cant factor associated with back-transitions, females
tended to be more likely to transition backwards
to CN from MCI, whereas back-transitions from
dementia seemed to be more likely in males. The pres-
ence of symptoms of depression was not shown to be
significantly associated with back-transitions, but the
data used in this study may not be sufficient for draw-
ing robust conclusions on the effect of depression.
According to the analysis, APOE 4 is a significant
factor associated with back-transitions from the MCI
state, with carriers of APOE 4 being less likely to
move backwards in the development of the disease.
In NACC, it was shown that this genetic factor is sig-
nificantly associated with back-transitions even from
an advanced disease state. The significant associa-
tion of this factor with back-transitions has also been
confirmed in autopsied subjects in other studies [9].
In general, our analyses showed that once a transition
to dementia has occurred, then only a few factors can
significantly affect the transition of individuals to an
earlier stage. This could of course arise due to the lim-
ited number of observations of people moving to the
MCI state after a previous classification to the demen-
tia state. However, it is also expected that this may
occur because once individuals reach a severe state,
they may no longer mask the serious and irreversible
changes in the brain.
The analysis performed in the current study has a
number of limitations. It is well known that all the
clinical states, and MCI in particular, are heteroge-
neous in the sense that a broad range of cognitive
abilities is covered within a state [9, 38]. Due to the
small sample size and insufficient information, we
have not considered any subtypes within the clinical
states. However, it is likely that the significant effect
of some of the factors considered might change, espe-
cially when subtypes of MCI and AD/dementia are
considered [6]. The outputs of the analysis may also
be affected by the duration of the studies and with-
drawal rates, as the clinical states that individuals will
reach in the future are not known. As such, and most
importantly, the analysis is censored with incomplete
outcome data on individuals. In addition, both ADNI
and NACC consist of highly selective populations
that are at a high risk of developing AD or other
dementias. The proportions of highly educated peo-
ple and ApoE 4 carriers are also higher than what
would be observed in a population-based sample. It
would thus be interesting to consider in future stud-
ies whether the present results can be validated in
population-based studies outside clinical settings.
The current study does not consider whether the
improvement in clinical outcome is connected to an
improvement in the pathological condition. Some
studies suggest that this is not necessarily true (see
also [9]). Misdiagnosis is very common for multiple
types of cognitive impairment and dementia, even
when using strict diagnosis criteria for the classifi-
cation of individuals in the different clinical states.
For AD in particular, it has been shown that a high
proportion, which can be up to 30%, of subjects diag-
nosed with probable AD, may not actually display
AD-typical neuropathological changes at autopsy
[12, 13]. A high number of misdiagnosis cases has
also been observed at the MCI state [9]. An analysis
of the transitions between states defined within the
NIA-AA research framework [36, 37], which focuses
on the diagnosis of AD with biomarkers (amyloid-
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deposition, pathologic tau, and neurodegeneration),
has also shown that in many cases, back-transitions
to less severe clinical states is not confirmed by the
improvement in the level of any of the biomarkers
used for the classification in the NIA-AA states. On
the other hand, we cannot rule out the possibility of
some of the back-transitions being real. One could
suggest that back-transitions are associated with a
slower progression towards AD and other dementias.
Although the numbers of individuals that transitioned
backwards but eventually reached dementia are very
small in our samples from two datasets, one can
show that the time required to reach the demen-
tia state since the first MCI diagnosis is higher for
back-transitioners compared to that of individuals
that developed dementia and had never moved back-
wards in disease development. This finding still needs
to be verified using studies with bigger samples and
longer follow-up, but it may suggest that in some
cases back-transitions are part of the process and an
indication of a slower dementia progression.
In either way, with the current diagnostic tools,
many factors can affect diagnosis and the occurrence
of back-transitions, ranging from lifestyle factors to
the presence of comorbidities. Indeed, due to such
factors, individuals can also be misclassified in any
of the more severe states. In the two datasets consid-
ered, many of the individuals that moved backwards
from the MCI state to the CN state either have never
reconverted to MCI, or they have moved again back to
MCI but have never developed dementia during the
study. Although individuals who transitioned back-
wards from MCI and have never transitioned again
back to MCI or have never developed dementia could
have pathological features similar to those in the MCI
group [9], these observations could support the idea
that in some cases there might be a misclassification
to the more severe state, although a longer follow-up
would be required in order to verify this. The analysis
of the datasets also showed that most of the peo-
ple who back-transitioned are classified in the more
severe states only for a short time. This may imply
that the accuracy in diagnosis increases over time and
that clinicians should potentially assess a longitudinal
follow-up of cognitive performance before the clas-
sification of individuals, at least at the MCI state. On
the other hand, this also raises questions about the
definition of the MCI state and the criteria used for
the classification of individuals to it, plus the relia-
bility of this state and whether it can be a real risk
state and precursor of AD or related dementias [3, 9,
34, 35]. It is worth noting that based on the physician
confidence in diagnosis score which is available only
in ADNI (in the ADNI-1 protocol) up to the first two
years in the study (in 3,867 assessments), in 54.6%
of the MCI diagnoses the clinician was not highly
confident when they made the diagnosis. The con-
fidence in diagnosis was higher at the healthy and
dementia stages; 80.8% of CN diagnoses and 64.3%
of the dementia diagnoses were made with high
confidence.
Whether the factors considered in this study facil-
itate the improvement of the cognitive state or
contribute to misdiagnosis remains uncertain and
it would be something interesting to investigate in
subsequent studies. The development of better diag-
nostic tools will enable an accurate description of the
clinical severity of AD and other dementias, and espe-
cially will aid in early detection of neuropathologic
changes. This will require the examination of, not
only a summary mental status score, but also a combi-
nation of biochemical and neuroimaging biomarkers,
taking into account the cognitive reserve hypothesis
and demographic plus genetic factors [21, 39].
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